KRAS and pancreatic neoplasm: These results suggest that oncogenic KRAS activates NF-κB signaling in human pancreas cancer, resulting in pharmacologically reversible changes to chemokine production that may participate in immune suppression or immune evasion within the pancreas cancer microenvironment.